You just read:

ViiV Healthcare presents phase III data from VIKING-3 study of dolutegravir in HIV-1 infected integrase inhibitor-resistant adults

News provided by

GLAXOSMITHKLINE INC.

Nov 16, 2012, 09:00 ET